Affiliations: Center of Experimental Orthopaedics, Saarland University Medical Center, University of the Saarland, Homburg/Saar, Germany | Department of Orthopaedic Surgery, Saarland University Medical Center, University of the Saarland, Homburg/Saar, Germany
Note: [] Address for correspondence: Magali Cucchiarini, PhD, Center of Experimental Orthopaedics, Kirrbergerstr. Bldg 37, Saarland University Medical Center, D-66421 Homburg/Saar, Germany. Tel.: +49 6841 1624 987; Fax: +49 6841 1624 988; E-mail: mmcucchiarini@hotmail.com.
Abstract: Adult articular cartilage has a limited capacity for self repair. Reproduction of a native structure and functional integrity in damaged cartilage remains a major problem in orthopaedic surgery. Strategies based on the implantation of genetically modified cells to sites of injury may provide workable options to treat articular cartilage lesions like those resulting from acute trauma or associated with the progression of osteoarthritis. Mesenchymal stem cells have remarkable properties that make them an attractive source of cells to treat cartilage disorders due to their self-renewal capability, stemness maintenance, and chondrogenic differentiation potential. For these reasons, such progenitor cells might be further modified by gene transfer protocols to reinforce their potency and consequently, to enhance the healing processes in damaged tissue following transplantation in sites of cartilage injury. Here, we propose an overview of the current approaches employed for cell- and gene-based treatment of articular cartilage disorders using mesenchymal stem cells.
